Regeneron is the last of 17 companies the administration pressed to commit to the "most favored nation" policy.

Regeneron is the last of 17 companies the administration pressed to commit to the "most favored nation" policy.

Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.